Top Markets
Coin of the day
NeuBase Therapeutics, Inc. NeuBase Therapeutics, Inc.

NeuBase Therapeutics, Inc.

NBSE
Classifica tra le azioni #39173
Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics,... Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics, Inc. is dedicated to pioneering therapeutic solutions for rare genetic disorders and various cancers stemming from aberrant genes. At the core of its approach is the proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform. This technology is being utilized to target ailments such as Huntington's disease (HD) and myotonic dystrophy, in addition to a broader spectrum of genetic conditions and applications within oncology. The company's leading therapeutic candidates encompass NT0100, a PATrOL-powered anti-gene therapy for Huntington's disease; NT0200, another PATrOL-enabled anti-gene solution for myotonic dystrophy type 1; and NT0300, a PATrOL-based treatment specifically engineered to address the mutated KRAS gene. NeuBase Therapeutics, Inc. maintains its headquarters in Pittsburgh, Pennsylvania.
Prezzo delle azioni
$0.378
Ultima sincronizzazione: 2024-05-24
Capitalizzazione di mercato
$618.41K
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia NeuBase Therapeutics, Inc. (NBSE)

Categoria

Storico del rendimento da dividendi per NeuBase Therapeutics, Inc. (NBSE)
Il rendimento da dividendi (TTM) di NeuBase Therapeutics, Inc. (simbolo azionario: NBSE) al 2026 è: 0
Rendimento medio negli ultimi 5 anni: 0.00%
Storico del rendimento da dividendi per NeuBase Therapeutics, Inc. (NBSE) da 2026 a 2026
Rendimento da dividendi alla fine di ogni anno (TTM)
Anno Rendimento da dividendi Cambia
Non abbastanza dati per le date fornite.
Rendimenti da dividendi (TTM) di aziende simili o concorrenti
Azienda Rendimento da dividendi Il paese
0.00%
US
0.00%
NL
0.00%
CH
0.00%
KR
0.65%
BE